Cargando…

Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy

Atherosclerotic cardiovascular diseases (ASCVD) are a very important cause of premature death. The most important risk factor for ASCVD is lipid disorders. The incidence of lipid disorders and ASCVD is constantly increasing, which means that new methods of prevention and treatment of these diseases...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sosnowska, Bożena, Surma, Stanisław, Banach, Maciej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781646/ https://www.ncbi.nlm.nih.gov/pubmed/36559024 http://dx.doi.org/10.3390/ph15121573

Ejemplares similares

Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia
por: Sosnowska, Bożena, et al.
Publicado: (2022)

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
por: Banach, Maciej, et al.
Publicado: (2023)

COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection
por: Surma, Stanisław, et al.
Publicado: (2021)

A look to the past – what has had the biggest impact on lipids in the last four decades? A personal perspective
por: Banach, Maciej, et al.
Publicado: (2023)

Fibrinogen and Atherosclerotic Cardiovascular Diseases—Review of the Literature and Clinical Studies
por: Surma, Stanisław, et al.
Publicado: (2021)

Nutrition, Nutraceuticals and Bioactive Compounds in the Prevention and Fight against Inflammation
por: Surma, Stanisław, et al.
Publicado: (2023)

Lipid-lowering therapies and achievement of LDL-cholesterol targets
por: Rizzo, Manfredi, et al.
Publicado: (2012)

Dietary salt intake and atherosclerosis: an area not fully explored
por: Banach, Maciej, et al.
Publicado: (2023)

Systematic Review: Evaluating the Effect of Lipid-Lowering Therapy on Lipoprotein and Lipid Values
por: Rosenson, Robert S., et al.
Publicado: (2013)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
por: Penson, Peter E., et al.
Publicado: (2020)

Could Lowering Phytosterol Absorption as Part of Lipid-Lowering Therapy Have a Beneficial Effect on Residual Risk?
por: Anagnostis, Panagiotis, et al.
Publicado: (2023)

Targeted Strategy in Lipid-Lowering Therapy
por: Dayar, Ezgi, et al.
Publicado: (2022)

Knowledge of Primary Care Patients Living in the Urban Areas about Risk Factors of Arterial Hypertension
por: Sobierajski, Tomasz, et al.
Publicado: (2023)

Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic
por: Katsiki, Niki, et al.
Publicado: (2020)

Curcumin - The Nutraceutical With Pleiotropic Effects? Which Cardiometabolic Subjects Might Benefit the Most?
por: Surma, Stanisław, et al.
Publicado: (2022)

Imatinib: A Breakthrough of Targeted Therapy in Cancer
por: Iqbal, Nida, et al.
Publicado: (2014)

Relationship between low-density lipoprotein cholesterol, lipid-lowering agents and risk of stroke: a meta-analysis of observational studies (n = 355,591) and randomized controlled trials (n = 165,988)
por: Banach, Maciej, et al.
Publicado: (2022)

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
por: Sharma, Geeta Geeta, et al.
Publicado: (2018)

Crizotinib: A Breakthrough for Targeted Therapies in Lung Cancer
por: Kwon, Jennifer, et al.
Publicado: (2012)

Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy
por: Lin, Yun, et al.
Publicado: (2010)

Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
por: Lee, Chih-Kuo, et al.
Publicado: (2021)

Osimertinib making a breakthrough in lung cancer targeted therapy
por: Zhang, Haijun
Publicado: (2016)

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
por: Pottier, Charles, et al.
Publicado: (2020)

Lipoprotein(a): the enemy that we still don’t know how to defeat
por: Banach, Maciej
Publicado: (2023)

Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol
por: Abdalwahab, Ahmed, et al.
Publicado: (2021)

Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
por: Banach, Maciej, et al.
Publicado: (2022)

Lipoprotein (a)—We Know So Much Yet Still Have Much to Learn …
por: Banach, Maciej
Publicado: (2016)

2022: the year in cardiovascular disease – the year of upfront lipid lowering combination therapy
por: Banach, Maciej, et al.
Publicado: (2022)

Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome
por: Wang, Qinqin, et al.
Publicado: (2020)

The Future of Lipid-Lowering Therapy
por: van Zwol, Willemien, et al.
Publicado: (2019)

Association of Lowering Low‐Density Lipoprotein Cholesterol With Contemporary Lipid‐Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta‐Analysis
por: Khan, Safi U., et al.
Publicado: (2019)

Low-density lipoprotein cholesterol lowering treatment: the current approach
por: Crismaru, Irina, et al.
Publicado: (2020)

Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
por: Greco, Maria Francesca, et al.
Publicado: (2020)

CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer
por: Bębnowska, Dominika, et al.
Publicado: (2020)

The Time Has Come for Targeted Therapies for AML: Lights and Shadows
por: Fiorentini, Alessandro, et al.
Publicado: (2020)

New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease
por: Burger, Achim Leo, et al.
Publicado: (2022)

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
por: Kosmas, Constantine E, et al.
Publicado: (2017)

Whole Body Cryotherapy and Hyperbaric Oxygen Treatment: New Biological Treatment of Depression? A Systematic Review
por: Krzystanek, Marek, et al.
Publicado: (2021)

Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?
por: Maphalle, Lehlogonolo N. F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l7vn8saavsle0kns52bk71v6m8